Alexion Pharmaceuticals Inc [ALXN]
$122.24 1.18 (0.95%)
Market Cap 27.09 Billion
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.
EPS 2.63 P/E Ratio 392.83
Previous Earnings Thu, Apr 25, 2019
Latest Earnings Wed, Jul 24, 2019 (In 6 days)
Pay Date --
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.